Results 71 to 80 of about 4,256 (179)

Hospitalisation Is a Strong Risk Factor for Discontinuation of Sodium‐Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are commonly withheld during hospitalisation because of concerns about diabetic ketoacidosis. We examined whether hospitalisation was associated with discontinuation of SGLT2i and compared patterns with another anti‐hyperglycaemic medicine without similar inpatient safety concerns ...
Tamara Y. Milder, Leah Shepherd, Hans Kristian Raket, Jerry R. Greenfield, Richard O. Day, Jialing Lin, Juliana de Oliveira Costa, Sophie Stocker, Carol A. Pollock, Brendon Neuen, Min Jun, Jane Ludington, Sallie‐Anne Pearson, Michael O. Falster   +13 more
wiley   +1 more source

Cardiorenal Mortality and Safety Outcomes of GLP‐1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m2: A Target Trial Emulation

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Cardiorenal evidence for glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) derives mainly from trials in overweight or obesity; data in adults with Type 2 diabetes (T2D) and body mass index (BMI) below 27 kg/m2 are limited. Materials and Methods We emulated a target trial in the TriNetX US Collaborative Network (index dates 2020 to ...
Shao‐Chia Chen, Yu‐Nan Huang, Pei‐Yun Li, Jo‐Ching Chen, Gideon Meyerowitz‐Katz, Shun‐Fa Yang, Pen‐Hua Su   +6 more
wiley   +1 more source

SGLT2 inhibitors preserve serum chloride in non-diabetic CKD: a propensity-matched and LASSO regression analysis

Renal Failure
Sodium–glucose cotransporter 2 inhibitors (SGLT2is) are novel renoprotective agents for patients with chronic kidney disease (CKD) and have diverse effects, including on the regulation of electrolyte balance.
Masaru Matsui, Takaaki Kosugi, Shunsuke Kitamura, Masatoshi Nishimoto, Akiko Itano, Marumi Yamamoto, Haruka Yabuta, Aiko Oda, Masato Kawakami, Hideo Tsushima, Keisuke Okamoto, Masahiro Eriguchi, Ken-ichi Samejima, Kazuhiko Tsuruya   +13 more
doaj   +1 more source

Temporal distribution of acute kidney injury–related hospitalizations after initiation of sodium–glucose cotransporter 2 inhibitors: A nationwide claims database analysis in older adults with an independent complementary single‐center eGFR analysis

Journal of Diabetes Investigation, EarlyView.
Among 190 older adults who experienced AKI‐related hospitalization after SGLT2 inhibitor initiation, 31.1% were hospitalized within 30 days. In an independent single‐center cohort, sustained early eGFR decline was associated with older age and use of one or two triple‐whammy‐related drug classes.
Kazuya Hiura, Ayana Tatsuno, Yamato Noto, Ryosuke Wakamatsu, Masayuki Sakunami, Ryu Kobayashi, Miki Yamashita   +6 more
wiley   +1 more source

Taking a Closer Look at Gliclazide – Benefits Beyond Glycemic Control

International Journal of Diabetes and Technology
The increasing prevalence of type 2 diabetes mellitus (T2DM) and the associated challenges in treatment are a cause of concern worldwide. Gliclazide is an oral antidiabetes drug used in the treatment of T2DM.
Alka Bishnoi, Amitabh Sur, Bensley Gonsalves, Bhawna Atri, Soumik Goswami, Venkatesan Ravindranath, Vivek Patel, Hiren Prajapati, Disha Shah   +8 more
doaj   +1 more source

Estrogen-induced cardiorenal protection: potential cellular, biochemical, and molecular mechanisms

American Journal of Physiology-Renal Physiology, 2001
A number of cellular and biochemical processes are involved in the pathophysiology of glomerular and vascular remodeling, leading to renal and vascular disorders, respectively. Although estradiol protects the renal and cardiovascular systems, the mechanisms involved remain unclear.
Dubey, Raghvendra K., Jackson, Edwin K.
openaire   +3 more sources

Sodium–glucose cotransporter 2 inhibitors for hypertension in cardiovascular–kidney–metabolic syndrome

Experimental Physiology, EarlyView.
Abstract The antihypertensive mechanism of sodium–glucose cotransporter 2 (SGLT2) inhibitors has been traditionally attributed to osmotic diuresis. However, emerging evidence reveals multifaceted mechanisms beyond diuresis, including regulation of the renin–angiotensin–aldosterone system, sympathetic nervous system suppression, ion homeostasis ...
Chunxiang Xu, Xingyu Qiu, Nan Xu, Gensheng Zhang, Enyin Lai, Liang Zhao   +5 more
wiley   +1 more source

Bibliometric analysis of SGLT2 inhibitor treatment for diabetic kidney disease

Renal Failure
Sodium-glucose co-transporter 2 (SGLT2) inhibitors show significant renoprotective potential for diabetic kidney disease, while comprehensive bibliometric analyses in this field are scarce.
Dan Hu, Liangmei Chen, Ruolan Mai, Tingmin Gao, Baozhang Guan   +4 more
doaj   +1 more source

Dietary interventions in acute kidney injury: From molecular mechanism to clinical trials

Experimental Physiology, EarlyView.
Abstract Ageing impairs renal resilience with an elevated risk of frequent and harmful acute kidney injury (AKI) that causes substantial morbidity and mortality among hospitalized patients. Since different damaging stimuli at the molecular, cellular and functional level contribute to this loss in kidney function, AKI's pathophysiology is heterogeneous ...
Felix C. Koehler, Pedro Rojas‐Morales, Roman‐Ulrich Müller   +2 more
wiley   +1 more source

Mineralocorticoid Receptor Antagonism in Diabetic Kidney Disease: From Pathophysiological Mechanisms to Clinical Paradigm Shifts

Diabetology
Diabetic kidney disease (DKD) remains a primary driver of end-stage kidney disease and cardiovascular morbidity despite the optimized use of renin–angiotensin system (RAS) inhibitors and sodium-glucose cotransporter-2 (SGLT2) inhibitors.
Gui-Hwa Jeong
doaj   +1 more source